Monitoring Of Bcr-abl Levels In Chronic Myeloid Leukemia Patients Treated With Imatinib In The Chronic Phase - The Importance Of A Major Molecular Response.

dc.creatorMachado, Melissa Pereira
dc.creatorTomaz, Juarez Pires
dc.creatorLorand-Metze, Irene
dc.creatorde Souza, Cármino Antonio
dc.creatorVigorito, Afonso Celso
dc.creatorDelamain, Marcia Torresan
dc.creatorBendit, Israel
dc.creatorPereira, Noemi Farah
dc.creatorPagnano, Katia Borgia Barbosa
dc.date2011
dc.date2015-11-27T13:22:10Z
dc.date2015-11-27T13:22:10Z
dc.date.accessioned2018-03-29T01:14:24Z
dc.date.available2018-03-29T01:14:24Z
dc.identifierRevista Brasileira De Hematologia E Hemoterapia. v. 33, n. 3, p. 211-5, 2011.
dc.identifier1806-0870
dc.identifier10.5581/1516-8484.20110056
dc.identifierhttp://www.ncbi.nlm.nih.gov/pubmed/23049298
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/199756
dc.identifier23049298
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1299989
dc.descriptionReal time PCR has become the most common technique to monitor BCR-ABL transcript levels of patients treated with kinase inhibitors. The aim of this study was to evaluate BCR-ABL levels of chronic myeloid leukemia patients treated with imatinib in the chronic phase and correlate the response to therapy and event-free survival. BCR-ABL levels were measured in peripheral blood cell samples using Real time PCR at diagnosis and then every 3 months after starting therapy with imatinib. Major molecular response was defined as a three-log reduction from the standardized baseline value. Major molecular response values were adjusted to international scale using a conversion factor of 1.19. The results are reported as a BCR-ABL/ABL ratio (%). Hematological, major cytogenetic and complete cytogenetic responses were achieved by 57 (95%), 45 (75%) and 38 (63%) patients, respectively. Twenty-four out of sixty patients achieved a major molecular response (40%) in a median time of 8.5 months. Overall survival and event free survival were higher for patients with (100%) versus patients without (77%) a complete cytogenetic response (p-value = 0.01) at 48 months. Patients with complete cytogenetic response and major molecular response had a higher event free survival compared to patients with complete cytogenetic response but without major molecular response (p-value = 0.007). In conclusion, the prognostic impact of achieving complete cytogenetic response and a major molecular response and also the importance of molecular monitoring in the follow-up of chronic myeloid leukemia patients were demonstrated.s.
dc.description33
dc.description211-5
dc.languageeng
dc.relationRevista Brasileira De Hematologia E Hemoterapia
dc.relationRev Bras Hematol Hemoter
dc.rightsaberto
dc.rights
dc.sourcePubMed
dc.subjectLeukemia, Myelogenous, Chronic, Bcr-abl Positive
dc.subjectMonitoring
dc.subjectPolymerase Chain Reaction
dc.titleMonitoring Of Bcr-abl Levels In Chronic Myeloid Leukemia Patients Treated With Imatinib In The Chronic Phase - The Importance Of A Major Molecular Response.
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución